The Most Important Psilocybin Study Yet? New Trial Finds Benefits Lasted a Full Year
Few people question whether psychedelic therapy works in the short term. It’s whether the benefits last that keeps people guessing.
Over the past decade, study after study has shown that psilocybin-assisted therapy can produce rapid and meaningful improvements in depression. People often describe feeling lighter, more connected, and more like themselves again after years of struggling.
But sceptics have always asked the same question: what happens six months later? Or a year later?
Do the improvements stick, or does the old depression slowly creep back in once the novelty wears off?
A major new study published in Psychotherapy and Psychosomatics offers the strongest answer yet.
The trial followed people with treatment-resistant depression for a full year after psilocybin-assisted therapy. According to researchers, the antidepressant effects remained remarkably stable throughout the entire follow-up period, with no meaningful decline between six months and twelve months. Basically magic mushrooms saw off the most stubborn form of depression for a whole year.
For a condition that’s notoriously difficult to treat, those findings could be hugely significant.
Why Treatment-Resistant Depression?
Not all depression looks the same. The participants in this study weren’t people experiencing a temporary low mood or their first depressive episode. They were living with therapieresistente depressie (TRD), one of the most challenging forms of the condition.
On average, participants had been dealing with major depression for nearly 14 years. Most had already tried multiple antidepressants without finding adequate relief, and more than three-quarters were also living with at least one additional psychiatric diagnosis.
In other words, this was a group for whom conventional treatments had largely fallen short. That’s what makes the results particularly noteworthy.
What Happened During the Trial?
The study took place across two German university hospitals and included 126 participants, making it the largest and most comprehensive long-term follow-up of any psychedelic clinical trial to date.
Participants received either one or two 25mg doses of psilocybin as part of a structured psychotherapy programme. The treatment wasn’t simply a dosing session. It included seven therapy sessions covering preparation, steun during the experience, and integratie afterwards. The controlled phase of the study lasted twelve weeks.
After that, participants were free to pursue whatever treatments they chose. Researchers then checked in again at six months en twelve months to see how everyone was doing.
This design allowed scientists to ask an important question: What happens after the formal treatment ends?
The Results Were Surprisingly Durable
At the beginning of the study, participants scored around 22 points on the Hamilton Depression Rating Scale, placing them firmly in the moderate-to-severe range of depression.
Six months later, average scores had dropped by roughly eight points, and at twelve months, those improvements were still there.
Not only had the gains persisted, but depression scores remained in the mild range overall. For researchers, one of the most important aspects of the findings was that participants didn’t receive any additional psilocybin during the follow-up period.
The improvements weren’t being maintained by repeated dosing. Instead, the results suggest that many participants experienced a lasting shift that continued long after the medicine had left their system.
Looking Beyond Average Scores
Average improvements tell part of the story, but researchers also looked at response rates. A clinical “response” was defined as a reduction of at least 50% in depression symptoms.
- At six months, 34% of participants met that threshold.
- At twelve months, that figure had actually risen slightly to 37%.
- Around 22% maintained continuous improvement from the end of treatment all the way through the year-long follow-up.
In a population where long-term recovery is often difficult to achieve, those numbers are encouraging.
An Unexpected Finding About Antidepressants
One of the study’s most interesting observations involved participants who restarted conventional antidepressant medication during the follow-up period. By twelve months, around one-third of participants had resumed antidepressants.
Researchers found that this group tended to have worse depression scores than those who had not restarted medication. On average, they scored about four points higher on the depression scale.
Importantly, the authors caution against drawing simplistic conclusions., the study does not suggest antidepressants caused poorer outcomes. A much more likely explanation is that people who were struggling more were naturally more inclined to seek additional treatment.
Still, the finding hints at something researchers have been discussing for years: psilocybin-assisted therapy may operate differently from conventional psychiatric medications.
A Different Model of Mental Health Treatment
Most depression treatments follow a familiar pattern. You take a medication regularly, your symptoms improve to some degree. The medication continues because stopping often means symptoms return.
The underlying assumption is ongoing management, however, these trial results point toward a different possibility. One or two carefully supported psychedelic experiences may be capable of producing changes that continue unfolding long after treatment ends.
Researchers describe this as potentially “salutogenic” or disease-modifying rather than merely symptom-suppressing.
Translated into everyday language, the idea is simple: Instead of continuously suppressing symptoms, psilocybin may help create conditions for deeper psychological change.
What Could Be Driving These Long-Term Effects?
Scientists are still working on the exact mechanisms, but several theories are gaining support.
One involves neuroplasticity — the brain’s ability to form new connections and adapt. Psilocybin appears to temporarily increase this flexibility, creating a window where entrenched patterns of thinking may become easier to change.
Another involves what’s known as the REBUS model, a neuroscience framework suggesting psychedelics relax rigid assumptions and deeply ingrained mental habits. This can allow new perspectives and emotional insights to emerge.
The psychedelic experience itself may also play an important role.
Many participants in psychedelic research describe profound shifts in meaning, identity, relationships, and life priorities. Those experiences can continue influencing behaviour long after the session has ended. As the study authors suggest, psilocybin may act less like a traditional pharmaceutical and more like a catalyst for psychological reorganisation.
The Limitations
Like all research, this study has limitations. There was no control group during the long-term follow-up period. Most participants were white, highly educated, and living in Germany. Researchers also couldn’t fully separate the influence of psychotherapy from the effects of psilocybin itself.
Future studies will need to address those questions, but limitations don’t erase what was observed.
Why This Study Matters
Psychedelic research often generates headlines focused on short-term breakthroughs, but this trial focuses on something arguably more important: durability.
Can meaningful improvements survive contact with everyday life?
For many participants in this study, the answer appears to be Ja.
Treatment-resistant depression is one of the hardest conditions in psychiatry to treat. Yet a substantial proportion of participants maintained clinically meaningful improvements for an entire year after just one or two psilocybin sessions combined with psychotherapy.
That doesn’t mean psilocybin is a miracle cure. But it does strengthen a growing body of evidence suggesting that psychedelic therapy may offer something genuinely different and more enduring than conventional approaches. In a field where long-term healing can be frustratingly rare, that’s a finding worth paying attention to.
